During a 15-year follow-up in 1 221 218 drug-naive patients with T2D, GLP-1RAs were associated with decreased risk for CRC compared with insulin (HR, 0.56; 95% CI, 0.44-0.72), metformin (HR, 0.75; 95% CI, 0.58-0.97), SGLT2 inhibitors, sulfonylureas, and thiazolidinediones, and with lower but not statistically significant risk compared with alpha-glucosidase or DPP-4 inhibitors (Figure, A). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.